Cargando…
Going beyond the mean: economic benefits of myocardial infarction secondary prevention
BACKGROUND: Using the example of secondary prophylaxis of myocardial infarction (MI), our aim was to establish a framework for assessing cost consequences of compliance with clinical guidelines; thereby taking cost trajectories and cost distributions into account. METHODS: Swiss mandatory health ins...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718707/ https://www.ncbi.nlm.nih.gov/pubmed/33276786 http://dx.doi.org/10.1186/s12913-020-05985-x |
_version_ | 1783619544554668032 |
---|---|
author | von Wyl, Viktor Ulyte, Agne Wei, Wenjia Radovanovic, Dragana Grübner, Oliver Brüngger, Beat Bähler, Caroline Blozik, Eva Dressel, Holger Schwenkglenks, Matthias |
author_facet | von Wyl, Viktor Ulyte, Agne Wei, Wenjia Radovanovic, Dragana Grübner, Oliver Brüngger, Beat Bähler, Caroline Blozik, Eva Dressel, Holger Schwenkglenks, Matthias |
author_sort | von Wyl, Viktor |
collection | PubMed |
description | BACKGROUND: Using the example of secondary prophylaxis of myocardial infarction (MI), our aim was to establish a framework for assessing cost consequences of compliance with clinical guidelines; thereby taking cost trajectories and cost distributions into account. METHODS: Swiss mandatory health insurance claims from 1840 persons with hospitalization for MI in 2014 were analysed. Included persons were predominantly male (74%), had a median age of 73 years, and 71% were pre-exposed to drugs for secondary prophylaxis, prior to index hospitalization. Guideline compliance was defined as being prescribed recommended 4-class drug prophylaxis including drugs from the following four classes: beta-blockers, statins, aspirin or P2Y(12) inhibitors, and angiotension-converting enzyme inhibitors or angiotensin receptor blockers. Health care expenditures (HCE) accrued over 1 year after index hospitalization were compared by compliance status using two-part regression, trajectory analysis, and counterfactual decomposition analysis. RESULTS: Only 32% of persons received recommended 4-class prophylaxis. Compliant persons had lower HCE (− 4865 Swiss Francs [95% confidence interval − 8027; − 1703]) and were more likely to belong to the most favorable HCE trajectory (with 6245 Swiss Francs average annual HCE and comprising 78% of all studied persons). Distributional analyses showed that compliance-associated HCE reductions were more pronounced among persons with HCE above the median. CONCLUSIONS: Compliance with recommended prophylaxis was robustly associated with lower HCE and more favorable cost trajectories, but mainly among persons with high health care expenditures. The analysis framework is easily transferrable to other diseases and provides more comprehensive information on HCE consequences of non-compliance than mean-based regressions alone. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12913-020-05985-x. |
format | Online Article Text |
id | pubmed-7718707 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-77187072020-12-07 Going beyond the mean: economic benefits of myocardial infarction secondary prevention von Wyl, Viktor Ulyte, Agne Wei, Wenjia Radovanovic, Dragana Grübner, Oliver Brüngger, Beat Bähler, Caroline Blozik, Eva Dressel, Holger Schwenkglenks, Matthias BMC Health Serv Res Research Article BACKGROUND: Using the example of secondary prophylaxis of myocardial infarction (MI), our aim was to establish a framework for assessing cost consequences of compliance with clinical guidelines; thereby taking cost trajectories and cost distributions into account. METHODS: Swiss mandatory health insurance claims from 1840 persons with hospitalization for MI in 2014 were analysed. Included persons were predominantly male (74%), had a median age of 73 years, and 71% were pre-exposed to drugs for secondary prophylaxis, prior to index hospitalization. Guideline compliance was defined as being prescribed recommended 4-class drug prophylaxis including drugs from the following four classes: beta-blockers, statins, aspirin or P2Y(12) inhibitors, and angiotension-converting enzyme inhibitors or angiotensin receptor blockers. Health care expenditures (HCE) accrued over 1 year after index hospitalization were compared by compliance status using two-part regression, trajectory analysis, and counterfactual decomposition analysis. RESULTS: Only 32% of persons received recommended 4-class prophylaxis. Compliant persons had lower HCE (− 4865 Swiss Francs [95% confidence interval − 8027; − 1703]) and were more likely to belong to the most favorable HCE trajectory (with 6245 Swiss Francs average annual HCE and comprising 78% of all studied persons). Distributional analyses showed that compliance-associated HCE reductions were more pronounced among persons with HCE above the median. CONCLUSIONS: Compliance with recommended prophylaxis was robustly associated with lower HCE and more favorable cost trajectories, but mainly among persons with high health care expenditures. The analysis framework is easily transferrable to other diseases and provides more comprehensive information on HCE consequences of non-compliance than mean-based regressions alone. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12913-020-05985-x. BioMed Central 2020-12-04 /pmc/articles/PMC7718707/ /pubmed/33276786 http://dx.doi.org/10.1186/s12913-020-05985-x Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article von Wyl, Viktor Ulyte, Agne Wei, Wenjia Radovanovic, Dragana Grübner, Oliver Brüngger, Beat Bähler, Caroline Blozik, Eva Dressel, Holger Schwenkglenks, Matthias Going beyond the mean: economic benefits of myocardial infarction secondary prevention |
title | Going beyond the mean: economic benefits of myocardial infarction secondary prevention |
title_full | Going beyond the mean: economic benefits of myocardial infarction secondary prevention |
title_fullStr | Going beyond the mean: economic benefits of myocardial infarction secondary prevention |
title_full_unstemmed | Going beyond the mean: economic benefits of myocardial infarction secondary prevention |
title_short | Going beyond the mean: economic benefits of myocardial infarction secondary prevention |
title_sort | going beyond the mean: economic benefits of myocardial infarction secondary prevention |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718707/ https://www.ncbi.nlm.nih.gov/pubmed/33276786 http://dx.doi.org/10.1186/s12913-020-05985-x |
work_keys_str_mv | AT vonwylviktor goingbeyondthemeaneconomicbenefitsofmyocardialinfarctionsecondaryprevention AT ulyteagne goingbeyondthemeaneconomicbenefitsofmyocardialinfarctionsecondaryprevention AT weiwenjia goingbeyondthemeaneconomicbenefitsofmyocardialinfarctionsecondaryprevention AT radovanovicdragana goingbeyondthemeaneconomicbenefitsofmyocardialinfarctionsecondaryprevention AT grubneroliver goingbeyondthemeaneconomicbenefitsofmyocardialinfarctionsecondaryprevention AT brunggerbeat goingbeyondthemeaneconomicbenefitsofmyocardialinfarctionsecondaryprevention AT bahlercaroline goingbeyondthemeaneconomicbenefitsofmyocardialinfarctionsecondaryprevention AT blozikeva goingbeyondthemeaneconomicbenefitsofmyocardialinfarctionsecondaryprevention AT dresselholger goingbeyondthemeaneconomicbenefitsofmyocardialinfarctionsecondaryprevention AT schwenkglenksmatthias goingbeyondthemeaneconomicbenefitsofmyocardialinfarctionsecondaryprevention |